US2022259643A1PendingUtilityA1

Methods and apparatus for detecting molecular interactions using fet arrays

Assignee: LIFE TECHNOLOGIES CORPPriority: Dec 14, 2006Filed: Mar 2, 2022Published: Aug 18, 2022
Est. expiryDec 14, 2026(~0.4 yrs left)· nominal 20-yr term from priority
H10D 30/68H10D 30/60C12Q 1/6825G01N 27/26C12Q 1/6869C12Q 1/6874G01N 33/54373G01N 33/6818G01N 27/4145G01N 27/4148H01L 29/788H01L 29/78
80
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Methods and apparatuses relating to large scale FET arrays for analyte detection and measurement are provided. ChemFET (e.g., ISFET) arrays may be fabricated using conventional CMOS processing techniques based on improved FET pixel and array designs that increase measurement sensitivity and accuracy, and at the same time facilitate significantly small pixel sizes and dense arrays. Improved array control techniques provide for rapid data acquisition from large and dense arrays. Such arrays may be employed to detect a presence and/or concentration changes of various analyte types in a wide variety of chemical and/or biological processes.

Claims

exact text as granted — not AI-modified
What is claimed: 
     
         1 . A method for identifying a sequence associated with a positive response to a particular active agent, comprising;
 sequencing a nucleic acid sequence from a first plurality of subjects that have exhibited a positive response and from a second plurality of subjects having a negative response to an active agent using one or more sequencing apparatuses, wherein each sequencing apparatus comprises an array of chemically-sensitive field effect transistors; and   identifying a common DNA sequence in the first plurality of subjects that have exhibited the positive response or from the second plurality of subjects that have exhibited the negative response that is not present in the first plurality of subjects.   
     
     
         2 . The method of  claim 1  wherein the first plurality of subjects and the second plurality of subjects are human subjects. 
     
     
         3 . The method of  claim 1  wherein the active agent is a therapeutic agent. 
     
     
         4 . The method of  claim 1 , wherein the nucleic acid sequence is a DNA sequence, and before sequencing, the method further comprises:
 preparing a plurality of nucleic acid sequences of a targeted size distribution for each DNA sample from the first plurality of subjects that have exhibited the positive response and from the second plurality of subjects having the negative response to the active agent.   
     
     
         5 . The method of  claim 4 , wherein the targeted size distribution is between 200 to 1000 base pairs in size. 
     
     
         6 . The method of  claim 4 , wherein the plurality of nucleic acid sequences is prepared using PCR-based amplification. 
     
     
         7 . The method of  claim 4 , further comprising:
 ligating adapter sequences on a 5′ and a 3′ end of each nucleic acid sequence of the plurality of nucleic acid sequences for each DNA sample; and   preparing a capture bead sample from the plurality of nucleic acid sequences for each DNA sample.   
     
     
         8 . The method of  claim 6 , wherein ligating adapter sequences includes providing a barcode for each nucleic acid sequence of the plurality of nucleic acid sequences for each DNA sample.

Join the waitlist — get patent alerts

Track US2022259643A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.